Document:

EX-10.13

 Exhibit 10.13 

EMPLOYMENT AGREEMENT 
 EMPLOYMENT
AGREEMENT (“Agreement”) made this 5th day of December 2011 between Dicerna Pharmaceuticals, Inc. (“Company”) on the one hand and James B. Weissman (the
“Executive”) on the other hand. 
 WHEREAS the Company desires to employ the Executive and the Executive desires to be employed by
the Company, on terms set forth herein; 
 NOW, THEREFORE, in consideration of the mutual agreements set forth herein, the parties agree as
follows: 
 1. Term of Employment. The Executive’s employment under this Agreement shall commence on January 1, 2012 and
shall end on such date as the Executive’s employment terminates in accordance with Section 4 of this Agreement. Subject to the balance of this Agreement, the Executive shall be an at-will employee of the Company whose employment may be
terminated (by the Company or by the Executive) at any time, for any or no reason, in which case the Executive will be entitled to the separation benefits set forth in Section 4, below. 

2. Duties. During his employment with the Company, the Executive shall have the title of Chief Business Officer. The Executive shall
devote his full business time and effort to the performance of his duties for the Company, which he shall perform faithfully and to the best of his ability. The Executive shall have all of the customary powers and duties associated with his position
and shall be subject to the Company’s policies, procedures, and approval practices, as generally in effect from time to time for all senior executives of the Company and the direction and oversight of the Company’s Board of Directors (the
“Board”). The Executive will report directly to the President and CEO of the Company. 
 3. Compensation and Related
Matters. 
 a. Base Salary. The Company shall pay the Executive base salary at a rate of $12,291.67 paid twice monthly (which
annualizes to $295,000), less withholdings and deductions required and/or permitted by law. The Executive’s base salary shall be paid in conformity with the Company’s payroll practices generally applicable to the Company’s senior
executives. 
 b. Bonus. 

i. Signing bonus. The Company shall pay the Executive a one-time signing bonus of $60,000, less applicable withholdings,
within the first fifteen (15) days of the Executive’s employment with the Company. The signing bonus is subject to the following repayment obligation: As a condition of the Executive’s employment with the Company and for receiving the
Signing Bonus, the Executive agrees that if, at any time during the twelve months following his first date of employment with the Company, the Executive (a) resigns his employment with the Company for any reason other than as provided for in
Section 4.b. and/or Section 4.e.iv. below, the Executive shall repay the Signing Bonus, less applicable withholdings deducted, to the Company on a pro-rated basis based on length of service; or (b) the Company terminates his
employment for 

 
Cause (as defined below), the Executive shall repay the Signing Bonus, less applicable withholdings deducted, to the Company, and in all cases specifically authorizes the Company to deduct all of
the Signing Bonus required to be repaid under this Agreement from his last paycheck and to the extent that there is a balance still owed by the Executive, the Executive will provide payment of such balance within thirty days (30) of his last
date of employment. The Executive will not be deemed to have earned the Signing Bonus if, for any reason, the Executive is not employed by the Company or if the Executive has given notice of termination or been notified of his termination at the
time such Signing Bonus is to be paid. 
 ii. Annual bonus. The Executive shall be eligible to be considered
for an Annual Bonus upon achieving of certain pre-determined performance targets consistent with any Incentive Compensation Plan established by the Board. The Annual Bonus shall be based, in part, on the Executive’s performance. The grant of
such a bonus shall be in the sole discretion of the Board. The maximum bonus amount for which the Executive will be eligible is thirty percent (30%) of base salary earned for the calendar year. The Annual Bonus will be earned only after it has
been granted by the Board. The Annual Bonus shall be paid to the Executive following the close of the fiscal year to which it relates, in no event later than March 15th of the calendar year
immediately following the calendar year in which it was earned. The Executive must be actively employed by the Company at the time the Board considers granting of bonuses to be eligible to receive such bonus. 

c. Stock/Stock Options. The Executive will receive, pursuant to the Company’s 2010 Employee, Director and Consultant Equity
Incentive Plan (the “Plan”), two incentive stock options (ISOs), dated the date that the Executive commences employment, each to purchase up to 400,000 shares of Common Stock (for a total of 800,000 shares) at an exercise price equal to
the Fair Market Value of each share on the date of grant. The first ISO will vest 25% after one year and then 1/36 at the end of each of the next 36 months. The second ISO will vest in 10,000 share increments, with one increment vesting per $1
million in non-equity cash derived from new business development activity (ie. existing deals will not be considered in determining vesting). However, this number will be $2 million for non-equity cash derived from a modification of
Dicerna’s relationships with Kyowa Hakko Kirin and Ipsen, if such modification occurs during the first six months after the commencement of employment. Both ISOs will fully accelerate upon Change of Control of the Company as defined in
herein. 
 d. Deal Incentive Cash. The Executive will be eligible to participate in the existing cash bonus plan whereby 1% of
non-equity cash derived from new business development activity will be paid out to Dicerna’s Executive Team. The distribution of cash within the Executive Team will be determined by the CEO and the Compensation Committee of the Board in a way
that recognizes relative contribution to the deal effort. 
 e. Benefits. During his employment, the Executive shall be
entitled to participate in all employee benefit plans and programs, including paid sick leave and holidays, life insurance, disability, medical, dental, and retirement savings plans, to the same extent generally available to senior executives of the
Company, in accordance with the terms of those plans and programs. The Executive shall be permitted up to four weeks of paid vacation per year, which will accrue 

  
 - 2 - 

 
on a monthly basis. The Executive will not be allowed to accumulate more than three weeks of unused vacation days at any given time. The Executive may carry over a maximum of five unused vacation
days from one calendar year to the next. 
 f. Expenses. The Company agrees to reimburse the Executive for reasonable out-of-pocket
expenses incurred in connection with Company business and within standards to be established by the Board from time to time, including, without limitation, travel and accommodations for authorized business trips, provided vouchers therefore, or
other supporting information as the Company may reasonably require, are presented to the Company. All reimbursements provided under this Agreement shall be made or provided in accordance with the requirements of Section 409A of the Internal
Revenue Code and the rules and regulations thereunder (“Section 409A”) including, where applicable, the requirement that (i) any reimbursement is for expenses incurred during the Executive’s lifetime (or during a shorter
period of time specified in this Agreement); (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year; (iii) the reimbursement of an
eligible expense shall be made no later than the last day of the calendar year following the year in which the expense is incurred; and (iv) the right to reimbursement or in kind benefits is not subject to liquidation or exchange for another
benefit. 
 g. Relocation and Moving Expenses 

i. Temporary accommodations. The Company agrees to reimburse the Executive for (a) the work-related traveling
between Ridgewood, NJ and Boston, and (b) for the temporary accommodations for the Executive up to $ 5,000 per month (or a figure agreed upon between the Executive and the Company for a fair standard of living accommodation) until the
earlier of (a) the move of his family to the Boston, Massachusetts area from Ridgewood, NJ or (b) April 30, 2012. 

ii. Relocation and moving. The Company also agrees to reimburse the Executive an amount up to $50,000, without prior
approval from the Company, for house hunting trips (maximum of 2), moving and relocation costs, travel from Ridgewood, NJ to Boston for the Executive and his immediate family, and related moving and relocation expenses for the Executive and his
immediate family’s move to the Boston, Massachusetts area. 
 iii. Reimbursement in case of early termination.
The amounts set forth in Sections 3.g.(i) and 3.g.(ii) above are hereinafter collectively referred to as the “Relocation Expenses”. The Executive will reimburse the Company for 50% of Relocation Expenses received by the Executive from
the Company if the Executive voluntarily resigns his employment from the Company at any time during the 6 month period immediately following such move. The reimbursement of Relocation Expenses and other expenses set forth in this
Sections 3.g.(i) and 3.g.(ii) will be grossed up for taxes, to the extent they are taxable as income to the Executive in accordance with the applicable sections of the Internal Revenue Code. 

  
 - 3 - 

 4. Termination 

a. Rights and Duties. The Executive is an employee “at will.” Accordingly, the Company or the Executive may terminate his
employment, at any time for any lawful reason, or no reason. The Executive and the Company agree that, without modifying or altering the Executive’s “at will” status, each will provide the other with at least thirty
(30) days’ prior written notice of termination of the Executive’s employment with the Company. If the Executive gives notice of termination, except in the case of a termination by the Executive for “Good Reason” as set forth
below, such notice will be deemed a voluntary resignation by the Executive and the Company, in its sole discretion, may elect to relieve the Executive of any obligation to perform duties during the notice period, waive the notice period and
immediately accept termination of the Executive’s employment, without changing the status of such termination as a voluntary resignation by the Executive. Should the Company in the event of a voluntary resignation decide to relieve the
Executive of any obligation to perform duties during the notice period, waive the notice period and immediately accept termination of the Executive’s employment, it shall nonetheless continue his compensation and benefits for the term of the
notice period, except that no bonus shall be earned or awarded during and after the notice period. 
 b. Termination for
“Good Reason.” The Executive may terminate his employment at any time for “Good Reason.” “Good Reason” shall comport with the requirements of Regulation §1.409A-1(n)(ii) and shall mean: 

i. A material diminution in the Executive’s authority, duties or responsibilities; 

ii. A material diminution by the Company of the Executive’s annual base compensation then in effect, except a
material diminution generally affecting the members of the Company’s management; 
 iii. Any action or inaction
by the Company that constitutes a material breach by the Company of the terms of this Agreement; or 
 iv. A
requirement that the Executive be based more than 50 miles from the offices at which he was principally employed immediately prior to the date of termination. 

The parties acknowledge and agree that “Good Reason” shall not be deemed to have occurred unless: (1) the Executive provides
the Company with written notice that he intends to terminate his employment hereunder for one of the Good Reason grounds set forth in Section 4.b. within sixty (60) days of the initial occurrence of such ground, with such notice containing
a description of such ground, (2) if such Good Reason ground is capable of being cured, the Company has failed to cure such ground within a period of thirty (30) days from the date of such written notice, and (3) the Executive
terminates his employment within ninety-one (91) days from the date that such Good Reason ground first occurs. For purposes of clarification, the above-listed conditions shall apply separately to each occurrence of a Good Reason ground, and
failure to adhere to such conditions in the event of the occurrence of grounds that would otherwise have constituted Good Reason had the conditions herein been satisfied shall not disqualify the Executive from asserting and satisfying the conditions
for Good Reason for any subsequent occurrence that may constitute Good Reason. 

  
 - 4 - 

 c. Termination by the Company for Cause. The Company may terminate the Executive’s
employment at any time for “Cause.” “Cause” shall mean: 
 i. The Executive’s commission of
an act of fraud or dishonesty which may or does adversely affect the Company; 
 ii. The Executive’s conviction
or plea of guilty or nolo contendere to or engaging in any felony or crime involving moral turpitude, fraud, misrepresentation or other crime and/or indictment for a crime that, in the reasonable opinion of the Company, affects the
Executive’s ability to perform the duties set forth in this Agreement and/or reflects negatively upon the Company; 

iii. Unauthorized disclosure by the Executive of the Company’s Proprietary Information, as defined in the Employee
Nondisclosure, Noncompetition, Nonsolicitation and Inventions Agreement which results or could have been reasonably foreseen to result, in a material financial loss to the Company; or 

iv. The Executive’s failure (which shall not include any Disability as defined below) or refusal to perform the
duties and responsibilities of his employment and/or to follow the policies and procedures of the Company, including without limitation the failure or refusal to carry out lawful instructions from the Board. If such failure or refusal is reasonably
possible of being cured in the opinion of the Company, then the Executive will be given thirty (30) days after written notice from the Company of such failure or refusal to cure. 

d. Termination in the Event of Death or Disability. The Agreement shall terminate upon the Executive’s death or Disability, and
the Executive’s employment with the Company shall thereupon terminate. For purposes of the Agreement, “Disability” is defined as any illness, injury, accident or condition of either a physical or psychological nature as a result of
which the Executive is unable to perform the essential functions of his duties and responsibilities hereunder for 90 days during any period of 365 consecutive calendar days or for any consecutive 90-day period. 

e. Effect of Termination. 

i. If the Executive is terminated by the Company for Cause, or by the Executive voluntarily other than for Good Reason,
then the Executive will only be entitled to payment when due of any unpaid base salary, expense reimbursements, and vacation days accrued prior to termination of employment. 

ii. If the Executive’s employment is terminated by the Company other than for Cause, or by the Company due to the
Executive’s Disability, or by the Executive for Good Reason (each of which will be deemed an involuntary termination), then the Executive will be entitled to payment when due of any unpaid base salary, expense reimbursements, and vacation days
accrued prior to termination of employment and, in 

  
 - 5 - 

 
exchange for the Executive’s execution of a separation agreement and general release provided by the Company and expressly subject to the conditions described in Section 4.e.v. below,
the following: 
 a) Continuation of the Executive’s base salary at the rate in effect as of the day immediately
preceding his date of termination for a six (6) month period, payable in accordance with the Company’s regular payroll practices, less applicable withholdings, commencing at the conclusion of the Review Period (as described below),
provided that the first installment of such payments shall include all amounts which would have been paid during the period between the Executive’s date of termination and the date of such first installment; and 

b) The Executive shall be eligible to continue health benefits pursuant to COBRA or the appropriate state equivalent. If
the Executive is eligible for and properly elects continuation of such coverage during the permissible time frame, the Company will pay the premiums for such group health insurance coverage for the shorter of (i) six (6) months or
(ii) until the Executive becomes eligible for health benefits through another employer or otherwise. After the shorter period, the Executive will be responsible for premium payments for continuation of such group health insurance coverage. 

iii. If the Agreement is terminated because of the Executive’s death, the Company shall pay to the estate of the
Executive the salary and benefits which would otherwise have been payable to the Executive up to the date of termination of his employment because of death. 

iv. In the event a Change of Control (as defined below) occurs and, if within one (1) year thereafter, the
Executive’s employment is terminated by the Company other than for Cause, or by the Company due to the Executive’s Disability, or by the Executive for Good Reason (each of which will be deemed an involuntary termination), then the
Executive will be entitled to payment when due of any unpaid base salary, expense reimbursements, and vacation days accrued prior to termination of employment and, in exchange for the Executive’s execution of a separation agreement and general
release provided by the Company and expressly subject to the conditions described in Section 4.e.v. below, the following: 

a) A lump sum payment equal to one (1) year of the Executive’s base salary at the rate in effect as of the day
immediately preceding his date of termination, less applicable withholdings, commencing at the conclusion of the Review Period (as described below); and 

b) The Executive shall be eligible to continue health benefits pursuant to COBRA or the appropriate state equivalent. If
the Executive is eligible for and properly elects continuation of such coverage during the permissible time frame, the Company will pay the premiums for such group health insurance coverage for the shorter of (i) twelve (12) months or
(ii) until the Executive becomes eligible for health benefits through another employer or otherwise. After the shorter period, the Executive will be responsible for premium payments for continuation of such group health insurance coverage. 

  
 - 6 - 

 For purposes of this Agreement, “Change of Control” means (A) the
occurrence of a merger or consolidation of the Company whether or not approved by the Board, other than (i) a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to
represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or the parent of such corporation) at least 50% of the total voting power represented by the voting securities of the Company or such
surviving entity or parent of such corporation outstanding immediately after such merger or consolidation, or (ii) a merger or consolidation which is in effect a financing transaction for the Company, including, but not limited to, a reverse
merger of the Company into a publicly traded “shell” company, or (B) the stockholders of the Company approve an agreement for the sale or disposition by the Company of all or substantially all of the Company’s assets, provided
that, in any case, “Change of Control” shall be in accordance with Regulation §1.409A-3(i)(5)(v). 

v. Payment of the severance pay and benefits described in Section 4.e.ii. or 4.e.iv., as applicable, is expressly
conditioned on the Executive’s execution without revocation of the separation agreement and general release described therein, and will commence immediately following a sixty (60) day period following the effective date of the
Executive’s separation from service from the Company (the “Review Period”). The separation agreement and general release will be provided to the Executive on or before the fifth
(5th) day following such separation from service. If the Executive fails or refuses to return such agreement within the Review Period, the applicable severance payments and benefits will be
forfeited. If the Executive is eligible for the severance pay and benefits described in Section 4.e.ii., then he shall not be eligible for and shall not receive the severance pay and benefits described in Section 4.e.iv. Similarly, if the
Executive is eligible for the severance pay and benefits described in Section 4.e.iv., then he shall not be eligible for and shall not receive the severance pay and benefits described in Section 4.e.ii. 

5. Nondisclosure, Noncompetition, Nonsolicitation and Inventions. As a condition of the Executive’s employment by the Company and
the payment of compensation and receipt of benefits referred to above, the Executive agrees to execute the attached standard Employee Nondisclosure, Noncompetition, Nonsolicitation and Inventions Agreement, in the form attached hereto as Exhibit A.
The Executive acknowledges that the Company would not offer him employment or provide compensation and/or benefits set forth above if he was not willing to be bound by the terms of such Agreement. 

  
 - 7 - 

 6. Notice. 

a. To the Company. The Executive will send all communications to the Company in writing, addressed as follows (or in any other manner
the Company notifies him to use): 
  

			
		  	Douglas M. Fambrough, Ph.D.
		  	President and CEO
		  	Dicerna Pharmaceuticals, Inc.
		  	480 Arsenal Street
		  	Building 1, Suite 120
		  	Watertown, MA 02472
		
	With a copy to:	  	 H. Andrew Matzkin, Esq.
 Mintz, Levin, Cohn,
Ferris, Glovsky and Popeo, P.C.
 One Financial Center
 Boston,
MA 02111

 b. To the Executive. All communications from the Company to the Executive relating to this Agreement
shall be sent to the Executive in writing, addressed as follows (or in any other manner he notifies the Company to use): 
  

					
		  	 James B. Weissman
 287 Ferris Place

Ridgewood, NJ 07450
	  	
			
	With a copy to:	  	  
	  	
		  	  
	  	
		  	  
	  	

 c. Time Notice Deemed Given. Notice shall be deemed to have been given when delivered or, if earlier
(1) three business days after mailing by United States certified or registered mail, return receipt requested, postage prepaid, or (2) faxed with confirmation of delivery, in either case, addressed as required in this section. 

7. Amendment. No provisions of this Agreement may be modified, waived, or discharged except by a written document signed by a Company
officer duly authorized by the Board and the Executive. A waiver of any conditions or provisions of this Agreement in a given instance shall not be deemed a waiver of such conditions or provisions at any other time in the future. 

8. Choice of Law; Forum Selection. The validity, interpretation, construction, and performance of this Agreement shall be governed by
the laws of the Commonwealth of Massachusetts without regard to its conflicts of laws principles. Any claims or legal actions by one party against the other regarding this Agreement shall be commenced and maintained exclusively in any state or
federal court located in the Commonwealth of Massachusetts, and the parties hereby submit to the jurisdiction and venue of any such court. 

9. Successors. This Agreement shall be binding upon, and shall inure to the benefit of, the Executive and his estate, but the Executive
may not assign or pledge this Agreement or any rights arising under it. Without the Executive’s consent, the Company may assign this Agreement to any affiliate or to a successor to substantially all the business and assets of the Company.

  
 - 8 - 

 10. Taxes; Code Sections 409A and 280G. 

a. The Company shall withhold taxes from payments it makes pursuant to this Agreement as it reasonably determines to be required by
applicable law. 
 b. If the benefits set forth in Section 4.e. of this Agreement constitute “non-qualified deferred
compensation” subject to Section 409A, then the following conditions apply to the payment of such benefits: 

i. Any termination of the Executive’s employment triggering payment of benefits under Section 4.e. must
constitute a “separation from service” under Section 409A(a)(2)(A)(i) of the Code and Treas. Reg. §1.409A-1(h) before distribution of such benefits can commence. To the extent that the termination of the Executive’s
employment does not constitute a separation of service under Section 409A(a)(2)(A)(i) of the Code and Treas. Reg. §1.409A-1(h) (as the result of further services that are reasonably anticipated to be provided by the Executive to the
Company at the time the Executive’s employment terminates), any benefits payable under Section 4.e. that constitute non-qualified deferred compensation under Section 409A shall be delayed until after the date of a subsequent event
constituting a separation of service under Section 409A(a)(2)(A)(i) of the Code and Treas. Reg. §1.409A-1(h). For purposes of clarification, this Section shall not cause any forfeiture of benefits on the Executive’s part, but
shall only act as a delay until such time as a “separation from service” occurs. 
 ii. If the Executive is
a “specified employee” (as that term is used in Section 409A and regulations and other guidance issued thereunder) on the date his separation from service becomes effective, any benefits payable under Section 4.e. that constitute
non-qualified deferred compensation subject to Section 409A shall be delayed until the earlier of: (A) the business day following the six-month anniversary of the date his separation from service becomes effective, or (B) the date of
the Executive’s death, but only to the extent necessary to avoid the adverse tax consequences and penalties under Section 409A. On the earlier of: (A) the business day following the six-month anniversary of the date his separation
from service becomes effective, or (B) the Executive’s death, the Company shall pay the Executive in a lump sum the aggregate value of the non-qualified deferred compensation that the Company otherwise would have paid the Executive prior
to that date under Section 4.e. 
 iii. It is intended that each installment of the payments and benefits
provided under Section 4.e. shall be treated as a separate “payment” for purposes of Section 409A. 

iv. Neither the Company nor the Executive shall have the right to accelerate or defer the delivery of any such payments
or benefits except to the extent specifically permitted or required by Section 409A. 
 c. Notwithstanding any other provision
of this Agreement to the contrary, in the event of any ambiguity in the terms of this Agreement, such term(s) shall be interpreted and at all times administered in a manner that avoids the inclusion of compensation in income under Section 409A,
or the payment of increased taxes, excise taxes or other penalties under Section 409A. 

  
 - 9 - 

 d. The parties intend this Agreement to be in compliance with Section 409A. Executive
acknowledges and agrees that Company does not guarantee the tax treatment or tax consequences associated with any payment or benefit arising under this Agreement, including but not limited to consequences related to Section 409A. 

e. If any payment or benefit the Executive would receive under this Agreement, when combined with any other payment or benefit
Executive receives pursuant to a Change of Control (for purposes of this section, a “Payment”) would: (i) constitute a “parachute payment” within the meaning of Section 280G the Code; and (ii) but for this
sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then such Payment shall be either: (A) the full amount of such Payment; or (B) such lesser amount (with cash payments being
reduced before stock option compensation) as would result in no portion of the Payment being subject to the Excise Tax, whichever of the foregoing amounts, taking into account the applicable federal, state and local employments taxes, income taxes,
and the Excise Tax, results in Executive’s receipt, on an after-tax basis, of the greater amount of the Payment notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. 

11. Validity. The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of
any other provision of this Agreement, which shall remain in full force and effect. 
 12. Counterparts. This Agreement may be
executed in one or more counterparts, each of which shall be deemed to be an original but all of which together shall constitute the same instrument. 

13. Entire Agreement; Prior Agreements. This Agreement and any other agreement described in this Agreement, constitutes the entire
agreement among the parties with respect to the subject matter hereof and, unless otherwise provided herein, supersedes all prior agreements or understandings written or oral in respect thereof. 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 - 10 - 

							
		 		 	DICERNA PHARMACEUTICALS, INC.
			
	Date: December 5, 2011	 		 	 /s/ Douglas Fambrough

		 		 	By:	 	Douglas Fambrough
		 		 	Its:	 	President and CEO
			
		 		 	James B. Weissman
			
	Date: December 5, 2011	 		 	 /s/ James B. Weissman

  
 - 11 - 

 EXHIBIT A 

NONDISCLOSURE, NONCOMPETITION, NONSOLICITATION AND INVENTIONS 

AGREEMENT 
 This Nondisclosure,
Noncompetition and Assignment Agreement (the “Agreement”) is made by and between Dicerna Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and James B. Weissman (the “Employee”), as of
December 5, 2011. 
 The Employee acknowledges that his/her employment or the continuance of that employment with the Company is
contingent upon his/her agreement to sign and adhere to the provisions of this Agreement. In consideration of the employment or continued employment of the Employee by the Company, the Employee and the Company agree as follows: 

1. Duty to Devote Efforts. The Employee understands that his/her employment with the Company requires his/her undivided attention and effort
during normal business hours and excluding periods of vacation and sick leave to which he/she is entitled. As a result, during his/her employment with the Company, he/she shall not engage in any other employment, occupation, consulting or other
activity that conflicts with his/her obligations to the Company, whether directly related to the business in which the Company is involved during the term of his/her employment with the Company or otherwise. For the avoidance of doubt, the Employee
may engage in charitable, civic and educational activities and community affairs, provided that any such activities and affairs do not, in the aggregate, materially interfere with the proper performance of the Employee’s duties and
responsibilities to the Company. 
 2. Noncompetition. The Employee recognizes and agrees that the Company will suffer irreparable harm in
the event that the Employee enters into competition with the Company, either during or following the Employee’s employment with the Company. Therefore, the Employee agrees that while the Employee is employed by the Company and for a period of
two (2) years following the termination or cessation of such employment (the “Restricted Period”), regardless of the reasons, the Employee shall not, directly or indirectly, alone or as a consultant, partner, officer, director,
employee, joint venturer, lender or stockholder, or in any other capacity whatsoever, of any entity, (a) accept employment with any business or entity that is in competition with the products or services being conceived, designed, created,
developed, manufactured, marketed, distributed or sold by the Company, provided that nothing contained in this subsection (a) will prevent the Employee from being employed by a subsidiary, division, affiliate or unit (each, a “Unit”)
of an entity if that Unit is not engaged in any business which is in competition with the products or services being conceived, designed, created, developed, manufactured, marketed, distributed or sold by the Company, irrespective of whether some
other Unit of such entity engages in such competition; (b) engage in or undertake any business operations of conceiving, designing, creating, developing, manufacturing, marketing, distributing selling or rendering (or assisting any other person
in conceiving, designing, creating, developing, manufacturing, marketing, distributing selling or rendering) products or services that are in competition with the products or services being conceived, designed, created, developed, manufactured,
marketed, distributed, sold or rendered by the Company or (c) invest in or assist in any manner any business which directly or indirectly competes with the business or future business plans of the Company, except that he/she may own up to one
percent (1%) of the outstanding securities of any corporation having a class of equity 

  
 - 12 - 

 
securities actively traded on a national securities exchange or on the NASDAQ Stock Market. A business or entity shall be deemed to be in competition with the products or services being
conceived, designed, created, developed, manufactured, marketed, distributed, sold or rendered by the Company if it is in the business of development, manufacture, license, sale and distribution of RNAi-based therapeutic and diagnostic products
(including, but not limited to, DsiRNA technology). The geographic scope of this Section 2 shall extend to anywhere the Company is doing business, has done business or intends to do business. The Employee acknowledges and agrees that if he/she
violates any of the provisions of this Section 2, the Restricted Period will be extended from the date of termination of employment for a period equal to any period during which he/she engages in such violation(s), whether such period is during
the pendency of litigation or otherwise. 
 3. Nonsolicitation of Customers. The Employee recognizes and agrees that the clients, customers
and accounts of the Company, which the Company now or hereafter services during the Employee’s employment with the Company, and all prospective clients, customers and accounts from whom the Employee has solicited business while in the employ of
the Company, shall be solely the clients, customers and accounts of the Company. Therefore, the Employee agrees that while the Employee is employed by the Company and for a period of two (2) years following the termination or cessation of
such employment, regardless of the reasons, the Employee shall not, directly or indirectly, alone or as a consultant, partner, officer, director, employee, joint venturer, lender or stockholder, or in any other capacity whatsoever, of any entity,
solicit, divert or take away, attempt to divert or to take away, any client, customer or account of the Company, or any potential client, customer or account of the Company which were contacted, solicited or served by the Employee while employed by
the Company or about whom the Employee obtained or became familiar with through Confidential Information (as defined in Section 5). The geographic scope of this Section 3 shall extend to anywhere the Company is doing business, has done
business or intends to do business. 
 4. Nonsolicitation of Employees. The Employee recognizes and agrees that the Company has invested
substantial resources and effort in assembling its present staff and personnel. Therefore, the Employee agrees that while the Employee is employed by the Company and for a period of two (2) years following the termination or cessation of such
employment, regardless of the reasons, the Employee shall not, directly or indirectly: (i) recruit, solicit or hire any employee of the Company; or (ii) induce or attempt to induce any employee of the Company to terminate his/her
employment with, or otherwise cease his/her relationship or engagement with, the Company. 
 5. Nondisclosure. The Employee agrees that all
Confidential Information (as defined below), whether or not disclosed orally or in writing, is and shall be the exclusive property of the Company. The Employee shall not at any time, whether during or after the termination or cessation of his/her
employment, without written authorization of the Chief Executive Officer of the Company, unless and until the Confidential Information has become public knowledge without fault by the Employee, (a) reveal any Confidential Information to any
person or entity, except to employees of the Company who need to know such Confidential Information for the purposes of their employment, (b) use or attempt to use any Confidential Information for any purposes (other than in the ordinary course
of performing his/her duties as an employee of the Company), or (c) use any Confidential Information in any manner which may 

  
 - 13 - 

 
injure or cause loss or may be calculated to injure or cause loss to the Company, whether directly or indirectly. The term “Confidential Information” shall include any information
concerning the organization, business, business relationships or finances of the Company or of any third party which the Company is under an obligation to keep confidential or that is maintained by the Company as confidential. Such Confidential
Information shall include, but is not limited to, trade secrets or confidential information respecting inventions, products, designs, methods, know-how, techniques, systems, processes, specifications, blueprints, engineering data, software programs,
works of authorship, clinical testing programs, marketing material, customer lists, customer information, financial information, pricing information, personnel information, business plans or strategy, projects, plans and proposals. 

6. Company Property. 
 a. The
Employee agrees that Company Property (as defined below) shall be and is the exclusive property of the Company to be used by the Employee only in the performance of his/her duties for the Company and further agrees that during his/her employment
with the Company, or after the termination or cessation of such employment, he/she shall not make, use or permit to be used any Company Property otherwise than for the benefit of the Company. All such Company Property or copies thereof and all
tangible property of the Company in the custody or possession of the Employee shall be delivered to the Company, upon the earlier of (i) a request by the Company or (ii) upon the termination or cessation of the Employee’s employment.
After such delivery, the Employee shall not retain any such Company Property or copies thereof or any other tangible property. The term “Company Property” shall include all files, letters, notes, memoranda, reports, lists, records,
drawings, sketches, laboratory notebooks, specifications, software programs, software code, data, computers, cellular telephones, pagers, credit and/or calling cards, keys, access cards, documentation or other materials of any nature and in any
form, whether written, photographic, printed, electronic or in digital format or otherwise, relating to any matter within the scope of the business of the Company or concerning any of its dealings or affairs and any other Company property in
Employee’s possession, custody or control. 
 b. The Employee agrees that his/her obligation not to disclose or to use information and
materials of the types set forth in Section 6(a) above, and his/her obligation to return materials and tangible property, set forth in Section 6(a) above, also extends to such types of information, materials and tangible property of
clients, customers and accounts of the Company or suppliers to the Company or other third parties who may have disclosed or entrusted the same to the Company or to the Employee. 

7. Assignment of Developments. 

a. If at any time or times during Employee’s employment with the Company or prior to the Employee’s employment with the Company when
working with, for, or on behalf of the Company in a capacity other than as an employee, he/she did or shall (either alone or with others) make, conceive, create, discover, invent or reduce to practice, whether or not during normal working hours or
on the premises of the Company, any Development that (i) relates to the business of the Company or any customer of or supplier to the Company or any of the products or services being developed, manufactured or sold by the Company or which may
be 

  
 - 14 - 

 
used in relation therewith; (ii) results from tasks assigned to the Employee by the Company; or (iii) results from the use of premises or personal property (whether tangible or
intangible) owned, leased or contracted for or by the Company, then all such Developments and the benefits thereof are and shall immediately become the sole and absolute property of the Company and its assigns, as works made for hire or otherwise.
The term “Development” shall mean any invention, modification, discovery, design, development, improvement, process, software program, work of authorship, documentation, formula, data, technique, know-how, trade secret or intellectual
property right whatsoever or any interest therein (whether or not patentable or registrable under copyright, trademark or similar statutes). The Employee shall fully and promptly disclose to the Company (or any persons designated by it) each such
Development. To the extent not already owned by the Company, the Employee agrees to assign and does hereby assign to the Company (or any person or entity designated by the Company) all his/her right, title and interest (including, but not limited
to, rights to inventions, patentable subject matter, copyrights and trademarks) in and to the Developments and all benefits and/or rights resulting therefrom to the Company and its assigns without further compensation and shall communicate, without
cost or delay, and without disclosing to others the same, all available information relating thereto (with all necessary plans and models) to the Company. The Employee also hereby waives all claims to moral rights in any Developments. 

b. Excluded Developments. This Section 7 shall not apply to Developments which do not relate to the present or planned business or
research and development of the Company and which are made and conceived by the Employee not during normal working hours, not on the Company’s premises and not using the Company’s tools, devices, equipment or Confidential Information, but
shall apply to past Developments, including Developments made prior to the Employee’s employment as an employee. The Employee represents that the Developments identified in the Appendix, if any, attached hereto comprise the complete list of all
the Developments that the Employee has made or conceived or otherwise claimed ownership prior to his/her employment by the Company, which Developments are excluded from this Agreement. The Employee understands that it is only necessary to list the
title of such Developments and the purpose thereof but not details of the Development itself. IF THERE ARE ANY SUCH DEVELOPMENTS TO BE EXCLUDED, THE UNDERSIGNED SHOULD INITIAL HERE; OTHERWISE IT WILL BE DEEMED THAT THERE ARE NO SUCH EXCLUSIONS. 

8. Further Assurances. The Employee agrees to cooperate fully with the Company, both during and after his/her employment with the Company,
with respect to the procurement, maintenance and enforcement of copyrights, patents and other intellectual property rights (both in the United States and foreign countries) relating to Developments. The Employee shall, during his/her employment and
at any time thereafter, at the request and cost of the Company, promptly sign, execute, make and do all such deeds, documents, acts and things as the Company and its duly authorized officers may reasonably require: 

a. to apply for, obtain, register and vest in the name of the Company alone (unless the Company otherwise directs) patents, copyrights,
trademarks or other analogous protection in any country throughout the world relating to a Development and when so obtained or vested to renew and restore the same; and 

  
 - 15 - 

 b. to defend any judicial, opposition or other proceedings in respect of such applications and
any judicial, opposition or other proceeding, petition or application for revocation of any such patent, copyright, trademark or other analogous protection. 

The Employee further agrees that if the Company is unable, after reasonable effort, to secure the Employee’s signature on any such
papers, application for patent, copyright, trademark or other analogous protection, or other documents regarding any legal protection relating to a Development, whether because of the Employee’s physical or mental incapacity or for any other
reason whatsoever, the Employee hereby irrevocably designates and appoints the Company and its duly authorized officers and agents as the Employee’s agent and attorney-in-fact, to act for and on his/her behalf and stead to execute and file any
such papers, application or applications or other documents and to do any and all other lawfully permitted acts to further the prosecution and issuance of patent, copyright or trademark registrations or any other legal protection thereon with the
same legal force and effect as if executed by the Employee. 
 9. Employment At Will. The Employee understands that this Agreement does not
constitute an implied or written employment contract and that his/her employment with the Company is on an “at-will” basis. Accordingly, the Employee understands that either the Company or the Employee may terminate Employee’s
employment at any time, for any or no reason, with or without prior notice. 
 10. Severability. The Employee hereby agrees that each
provision and the subparts of each provision herein shall be treated as separate and independent clauses, and the unenforceability of any one clause shall in no way impair the enforceability of any of the other clauses of the Agreement. Moreover, if
one or more of the provisions contained in this Agreement shall for any reason be held to be excessively broad as to scope, activity, subject or otherwise so as to be unenforceable at law, such provision or provisions shall be construed by the
appropriate judicial body by limiting or reducing it or them, so as to be enforceable to the maximum extent compatible with the applicable law as it shall then appear. The Employee hereby further agrees that the language of all parts of this
Agreement shall in all cases be construed as a whole according to its fair meaning and not strictly for or against either of the parties. 

11. Amendments; Waiver. Any amendment to or modification of this Agreement, or any waiver of any provision hereof, shall be in writing and
signed by the Company. No delay or omission by the Company in exercising any right under this Agreement or any waiver by the Company of a breach of any provision of this Agreement shall not operate or be construed as a waiver of that right or any
subsequent breach of such provision or any other provision hereof. 
 12. Survival. This Agreement shall be effective as of the date entered
below. The Employee’s obligations under this Agreement shall survive the termination or cessation of his/her employment regardless of the manner of such termination or cessation and shall be binding upon his/her heirs, executors, administrators
and legal representatives. 
 13. Assignment. The term “Company” shall include Dicerna Pharmaceuticals, Inc. and any of its
subsidiaries, divisions, or affiliates. The Company shall have the right to assign this Agreement to its successors and assigns, and all covenants and agreements hereunder shall inure to the benefit of and be enforceable by said successors or
assigns. The Employee may not assign this Agreement. 

  
 - 16 - 

 14. Representations. 

a. The Employee hereby represents that, except as the Employee has disclosed in writing to the Company, the Employee is not bound by the terms
of any agreement with any previous employer or other party to refrain from using or disclosing any trade secret or confidential or proprietary information in the course of his/her employment with the Company or to refrain from competing, directly or
indirectly, with the business of such previous employer or any other party. The Employee further represents that his/her performance of all the terms of this Agreement and as an employee of the Company does not and will not breach any agreement to
keep in confidence proprietary information, knowledge or data acquired by the Employee in confidence or in trust prior to his/her employment with the Company, and the Employee will not disclose to the Company or induce the Company to use any
confidential or proprietary information or material belonging to any previous employer or others. The Employee further represents that he/she has returned all property and confidential information belonging to all prior employers. To the extent that
Employee has retained any non-confidential and non-proprietary materials and documents of a prior employer, such materials and documents have been disclosed in writing to the Company. 

b. The Employee hereby represents that his/her employment with the Company, the execution of this Agreement and his/her performance of all of
the terms of this Agreement do not and will not conflict with or breach the terms of any other agreement by which the Employee is bound (including, but not limited to, to keeping in confidence proprietary information acquired by the Employee in
confidence or in trust prior to his/her employment by the Company). The Employee further represents that he/she shall not enter into any agreement, either written or oral, in conflict herewith. 

c. The restrictions contained in this Agreement are necessary for the protection of the business and goodwill of the Company and are
considered by the Employee to be reasonable for such purpose. The Employee agrees that any breach of this Agreement by him/her is likely to cause substantial and irreparable damage to the Company and that in the event of such breach the Company
shall have, in addition to any and all remedies of law, the right to an injunction, specific performance or other equitable relief to prevent the violation of the Employee’s obligations hereunder. The Company may apply for such injunctive
relief in any court of competent jurisdiction without the necessity of posting any bond or other security. 
 15. Governing Law; Forum
Selection Clause. This Agreement and any claims arising out of this Agreement (or any other claims arising out of the relationship between the parties) shall be governed by and construed in accordance with the laws of the Commonwealth of
Massachusetts, without application of the conflict of laws principles thereof. Any claims or legal actions by one party against the other shall be commenced and maintained in any state or federal court located in the Commonwealth of Massachusetts,
and the parties hereby submit to the jurisdiction and venue of any such court. 

  
 - 17 - 

 16. Entire Agreement. This Agreement sets forth the complete, sole and entire agreement between
the parties on the subject matter herein and supersedes any and all other agreements, negotiations, discussions, proposals, or understandings, whether oral or written, previously entered into, discussed or considered by the parties. The Employee
agrees that any change or changes in his/her duties, salary or compensation after the signing of this Agreement shall not affect the validity or scope of this Agreement. 

THE EMPLOYEE ACKNOWLEDGES THAT HE/SHE HAS CAREFULLY READ THIS AGREEMENT AND UNDERSTANDS AND AGREES TO ALL OF THE PROVISIONS IN THIS AGREEMENT.

 IN WITNESS WHEREOF, the undersigned has executed this Agreement as a sealed instrument as of the 5 day of December, 2011. 

 

			
	Signature:	 	 /s/ James B. Weissman

		
	Name (Please Print):	 	James B. Weissman
		
	Address:	 	287 Ferris Place
		 	Ridgewood, NJ 07450

 ACKNOWLEDGED BY: 
  

			
	DICERNA PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Douglas Fambrough

		
	Name:	 	Douglas Fambrough
		
	Title:	 	CEO

  
 - 18 - 

 APPENDIX – TITLE/PURPOSE OF DEVELOPMENTS 

The following is a complete list of all Developments and the purpose of those Developments: 

                No Developments 

                See Below 

Developments and purpose:EX-10.14

 Exhibit 10.14 

DICERNA PHARMACEUTICALS, INC. 

480 Arsenal Street 

Building 1, Suite 120 

Watertown, MA 02472 

        June 2, 2009 

David Madden 
 210 Wood Road 

Bedford Corners, NY 10549 
 Dear Mr. Madden: 

On behalf of the Board of Directors, I am pleased to offer you the position of Chairman of the Board of Directors of Dicerna Pharmaceuticals,
Inc. (the “Company”). Should you accept this position, and upon your election by the Company’s Board of Directors, the following outlines some of the key elements applicable to your role as Chairman of the Board of Directors of
the Company. 
 1. Service. You will serve as Chairman for an initial period of one (1) year or until your earlier resignation
or removal as Chairman or as a Director of the Company. Under Delaware law and the Company’s Certificate of Incorporation, By-laws and other applicable corporate documents, you may resign as Chairman or as a Director at any time, and you may be
removed at any time as a member of the Board of Directors by the Company stockholders and as Chairman by the Board of Directors. After the initial one-year term, you may continue as Chairman upon your mutual agreement with the Company and its Board
of Directors. 
 2. Meetings. We expect to hold meetings of the Board of Directors at least six (6) times per year. We also
expect from time to time to call special meetings of the Board of Directors. As Chairman, it is expected that you will use your reasonable best efforts to attend all meetings of the Board of Directors and any committees on which you serve and that
you will be available to the Company for consultation and discussion on key strategic initiatives of the Company. 
 3. Compensation.
In consideration of your services described above, the Company will provide you with the following: 
 (a) Cash Payment. The Company
will pay you an annual cash retainer of $75,000, payable monthly in arrears in accordance with the Company’s normal payment practices for each year of your service as a member of the Board of Directors. 

(b) Expenses. The Company will reimburse you for the reasonable
out-of-pocket expenses incurred by you in attending meetings of the Board of Directors and of any committee on which you may serve upon submission by you of reasonable
supporting documentation. 

 David Madden 

June 2, 2009 
  Page
 2
 
  

 (c) Option Grants. 

(i) Initial Option. Upon your appointment by the Board of Directors as Chairman of the Company and the approval by the Company’s
Board of Directors, you will be issued an option (the “Initial Option”) to purchase 300,000 shares (the “Option Shares”) of the Company’s common stock, $.0001 par value per share (the “Common
Stock”), which Option Shares shall equal one percent (1%) of the outstanding shares of Common Stock of the Company as of the date hereof, calculated on a fully-diluted, as-converted basis (the “Initial Percentage Ownership
Amount”). Twenty-five percent (25%) of the Option Shares shall vest on the first anniversary of the date of grant of the Initial Option, and the remaining seventy-five percent (75%) of the Option Shares shall vest monthly
thereafter over the subsequent three years subject to your continued service to the Company as a member of the Board of Directors. The Initial Option shall be exercisable at a price per share equal to the fair market value of the Common Stock of the
Company on the date of grant of the Initial Option. 
 (A) Additional Option. Upon the consummation by the Company of an equity
financing in which shares of preferred stock senior in liquidation preference to the Company’s Series A Convertible Preferred Stock (the “Senior Preferred Stock”) are issued and sold by the Company (the
“Financing”), then, upon approval by the Company’s Board of Directors, you will receive an additional option (the “Additional Option”) to purchase that number of shares of Common Stock of the Company as shall
equal the Additional Percentage Ownership Amount of the Fully Diluted Financing Shares issued in connection with the Financing. As used herein, (A) the term “Additional Percentage Ownership Amount” shall be determined as
follows: (1) in the event that the price per share of the Senior Preferred Stock issued and sold by the Company in the Financing equals $1.00, the Additional Percentage Ownership Amount shall equal one percent (1%), (2) in the event that
the price per share of the Senior Preferred Stock issued and sold by the Company in the Financing exceeds $1.00, the Additional Percentage Ownership Amount shall equal one percent (1%) plus .01% for each $.01 that such per share price exceeds
$1.00, and (3) in the event that the price per share of the Senior Preferred Stock issued and sold by the Company in the Financing is less than $1.00, the Additional Percentage Ownership Amount shall equal one percent (1%) less .01% for
each $.01 that such purchase price is less than $1.00; and (B) the term “Fully Diluted Financing Shares” means the aggregate number of shares of Common Stock of the Company issued in connection with the Financing, calculated on
a fully-diluted, as-converted basis as of the closing date of such Financing (including, without limitation, any additional shares of Common Stock that are authorized for issuance under the Company’s Third Amended and Restated 2007 Employee,
Director and Consultant Stock Plan in connection with the Financing). 
 The Additional Option shall be subject to vesting and shall have an exercise price
consistent with the terms set forth above for the Initial Option. 
 The Initial Option and the Additional Option that you receive hereunder shall be
subject to such further terms and conditions as will be specified in the Company’s Third Amended and Restated 2007 Employee, Director and Consultant Stock Plan and one or more non-qualified stock option agreements to be executed by you and the
Company. 

 David Madden 

June 2, 2009 
  Page
 3
 
  

 4. Indemnification. As a Delaware corporation, the Company has adopted provisions in
its Certificate of Incorporation and By-Laws to indemnify directors to the maximum extent allowed under Delaware law. In addition, the Company maintains a Directors and Officers’ insurance policy for certain claims made against directors and
officers. 
 5. Confidentiality. You agree that all Confidential Information (as defined below), whether or not disclosed orally or
in writing, is and shall be the exclusive property of the Company. You shall not at any time, whether during or after the termination or cessation of your service as a member of the Board of Directors of the Company, without the written
authorization of the Chief Executive Officer of the Company, unless and until the Confidential Information has become public knowledge without fault by you, (a) reveal any Confidential Information to any person or entity, except to employees of
the Company who need to know such Confidential Information, (b) use or attempt to use any Confidential Information for any purposes (other than in the ordinary course of performing your duties as a director of the Company), or (c) use any
Confidential Information in any manner which may injure or cause loss or may be calculated to injure or cause loss to the Company, whether directly or indirectly. The term “Confidential Information” shall include any information concerning
the organization, business, business relationships or finances of the Company or of any third party which the Company is under an obligation to keep confidential or that is maintained by the Company as confidential. Such Confidential Information
shall include, but is not limited to, trade secrets or confidential information respecting inventions, products, designs, methods, know-how, techniques, systems, processes, specifications, blueprints, engineering data, software programs, works of
authorship, clinical testing programs, marketing material, customer lists, customer information, financial information, pricing information, personnel information, business plans or strategy, projects, plans and proposals. 

 David Madden 

June 2, 2009 
  Page
 4
 
  

 If the foregoing is acceptable, please sign and return one copy to the undersigned at your earliest
convenience. On behalf of the Company and its Board of Directors, we look forward to working with you. 
  

	
	Very truly yours,
	
	/s/ Doug Fambrough
	
	Doug Fambrough, Ph.D.
	Chairman of the Board of Directors
	Dicerna Pharmaceuticals, Inc.

  

			
	Agreed to and Accepted:
	
	 /s/ David Madden

	David Madden
	Dated:	 	 7/6/09

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}]]